Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ubrogepant

- PMLiVE

Allergan’s oral migraine drug closer to US filing

New data keeps Allergan ahead of rival Biohaven

- PMLiVE

Shire rebuffs Takeda bids, as Allergan bows out

Allergan doesn’t intend to make a formal offer following a dip in its share prices

- PMLiVE

Amgen and Novartis migraine drug hits the mark again

Aimovig will become the first CGRP receptor-targeting drug if it reaches market

- PMLiVE

Allergan’s Avycaz breaks Gram-negative pneumonia antibiotic drought

Becomes the first new drug to treat the condition in over 15 years

- PMLiVE

EMA set to review Teva’s migraine injection

Fremanezumab could be approved for prophylactic use of migraines

Roche Basel Switzerland

Roche faces biosimilar blitz in 2018

Analysts predict copycat competitors will slow the Swiss group’s revenue growth

- PMLiVE

Amgen and Allergan win first EU approval for Avastin biosimilar

Mvasi, their version of Roche's blockbuster, is licensed for six types of cancers

- PMLiVE

Court throws out Allergan’s patent deal with Native American tribe

Rules the contentious agreement can't protect its dry eye treatment Restasis

- PMLiVE

NICE backs Allergan’s IBS therapy Truberzi

The £3 per day therapy was recommended in final guidance from the cost-effectiveness watchdog

- PMLiVE

Race to CGRP migraine drug finish line enters the final straight

US regulator keeps Aimovig ahead of competitors including Lilly’s galcanezumab

- PMLiVE

FDA panel backs Avastin and Herceptin biosimilars

A decision from the US regulator is expected in September

- PMLiVE

Allergan wins In-House Team of the Year at Communiqué

Faced with seismic change they focused on the business, its customers and people

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links